Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

cannabidiol/delta 9 tetrahydrocannabinol - Delphian Therapeutics

Next Previous
Drug Profile

cannabidiol/delta 9 tetrahydrocannabinol - Delphian Therapeutics

Alternative Names: CBD:THC - Delphian Therapeutics; S-1-220; S-1-221

Latest Information Update: 09 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Delphian Therapeutics Australia
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor agonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Migraine

Most Recent Events

  • 30 Aug 2025 Delphian Therapeutics Australia plans a phase I trial (In volunteers) in Australia (PO) (NCT07146945)
  • 28 Aug 2025 Preclinical trials in Migraine in Australia (PO) prior to August 2025
  • 30 Sep 2024 Delphian Therapeutics receives SBIR grant from National Institutes of Health (USA) for cannabidiol/delta 9 tetrahydrocannabinol development in Migraine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top